Targeting Fibroblast Growth Factor Pathways in Prostate Cancer

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2013 Sep 21

PMID 24052019

Citations 63

Authors

Paul G Corn

Fen Wang

Wallace L McKeehan

Nora Navone

Affiliations

Soon will be listed here.

Abstract

Advanced prostate cancer carries a poor prognosis and novel therapies are needed. Research has focused on identifying mechanisms that promote angiogenesis and cellular proliferation during prostate cancer progression from the primary tumor to bone-the principal site of prostate cancer metastases. One candidate pathway is the fibroblast growth factor (FGF) axis. Aberrant expression of FGF ligands and FGF receptors leads to constitutive activation of multiple downstream pathways involved in prostate cancer progression including mitogen-activated protein kinase, phosphoinositide 3-kinase, and phospholipase Cγ. The involvement of FGF pathways in multiple mechanisms relevant to prostate tumorigenesis provides a rationale for the therapeutic blockade of this pathway, and two small-molecule tyrosine kinase inhibitors-dovitinib and nintedanib-are currently in phase II clinical development for advanced prostate cancer. Preliminary results from these trials suggest that FGF pathway inhibition represents a promising new strategy to treat castrate-resistant disease.

Citing Articles

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.

Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M Med Oncol. 2025; 42(4):108.

PMID: 40087196 DOI: 10.1007/s12032-025-02675-8.

Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer.

Ding T, He L, Lin G, Xu L, Zhu Y, Wang X Chin J Cancer Res. 2025; 37(1):90-114.

PMID: 40078560 PMC: 11893346. DOI: 10.21147/j.issn.1000-9604.2025.01.07.

The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.

Huang M, Qin S, Gao H, Kim W, Xie F, Yin P Cells. 2024; 13(19.

PMID: 39404386 PMC: 11475995. DOI: 10.3390/cells13191622.

Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models.

Afshan S, Kim Y, Mattsson J, Akerfelt M, Harkonen P, Baumgartner M Cancer Med. 2024; 13(18):e70240.

PMID: 39300962 PMC: 11413502. DOI: 10.1002/cam4.70240.

FGFR1 governs iron homeostasis via regulating intracellular protein degradation pathways of IRP2 in prostate cancer cells.

Lin H, Lin S, Shi L, Xu G, Lin M, Li S Commun Biol. 2024; 7(1):1011.

PMID: 39154074 PMC: 11330447. DOI: 10.1038/s42003-024-06704-6.

References

McKeehan W, Wang F, Kan M . The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. 1998; 59:135-76. DOI: 10.1016/s0079-6603(08)61031-4. View

Kim J, Shin H, Cha S, Lee C, Hong B, Lim S . DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. Nat Commun. 2012; 3:1296. DOI: 10.1038/ncomms2313. View

Yang F, Zhang Y, Ressler S, Ittmann M, Ayala G, Dang T . FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013; 73(12):3716-24. PMC: 3686853. DOI: 10.1158/0008-5472.CAN-12-3274. View

Casci T, Vinos J, Freeman M . Sprouty, an intracellular inhibitor of Ras signaling. Cell. 1999; 96(5):655-65. DOI: 10.1016/s0092-8674(00)80576-0. View

Acevedo V, Gangula R, Freeman K, Li R, Zhang Y, Wang F . Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007; 12(6):559-71. DOI: 10.1016/j.ccr.2007.11.004. View

Kouhara H, Hadari Y, Schilling J, Bar-Sagi D, Lax I, Schlessinger J . A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 1997; 89(5):693-702. DOI: 10.1016/s0092-8674(00)80252-4. View

Schaeffer E, Marchionni L, Huang Z, Simons B, Blackman A, Yu W . Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008; 27(57):7180-91. PMC: 2676849. DOI: 10.1038/onc.2008.327. View

Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309. DOI: 10.1016/j.ccr.2005.09.005. View

Doll J, Reiher F, Crawford S, Pins M, Campbell S, Bouck N . Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate. 2001; 49(4):293-305. DOI: 10.1002/pros.10025. View

10.

Agarwal N, Sonpavde G, Sternberg C . Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol. 2012; 61(5):950-60. DOI: 10.1016/j.eururo.2011.12.028. View

11.

Choi S, Kim S, Choi J, Park C, Shim W, Lim D . Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem Cells Dev. 2008; 17(4):725-36. DOI: 10.1089/scd.2007.0230. View

12.

Wesche J, Haglund K, Haugsten E . Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437(2):199-213. DOI: 10.1042/BJ20101603. View

13.

Memarzadeh S, Xin L, Mulholland D, Mansukhani A, Wu H, Teitell M . Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell. 2007; 12(6):572-85. PMC: 2931420. DOI: 10.1016/j.ccr.2007.11.002. View

14.

Kirby M, Hirst C, Crawford E . Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11):1180-92. DOI: 10.1111/j.1742-1241.2011.02799.x. View

15.

Bai A, Meetze K, Vo N, Kollipara S, Mazsa E, Winston W . GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010; 70(19):7630-9. DOI: 10.1158/0008-5472.CAN-10-1489. View

16.

Beenken A, Mohammadi M . The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8(3):235-53. PMC: 3684054. DOI: 10.1038/nrd2792. View

17.

Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T . High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res. 1998; 58(10):2053-6. View

18.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

19.

Guo L, Degenstein L, Fuchs E . Keratinocyte growth factor is required for hair development but not for wound healing. Genes Dev. 1996; 10(2):165-75. DOI: 10.1101/gad.10.2.165. View

20.

Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G . Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate. 2002; 53(4):310-21. DOI: 10.1002/pros.10164. View